

V.I.M.COR  
BUY RECOMMENDATION

Medi-Hut		MHUT		\$ 7.90		Speculative	
52 WK PRICE RANGE		DIV YIELD		EPS		AVERAGE DAILY VOLUME MILL \$	
VAL MODEL	P/E LEAST GROWTH RT	PAST 5 YRS.	LATEST QUARTER	THIS YEAR	NEXT YEAR	NEXT 5 YRS.	
\$3.46-8.98	\$ 0.00 0.00 %	FY 2000 \$0.02	LATEST 12 MO \$ 0.03	FY 2001 \$ 0.09	FY 2002 \$ 0.20		\$
	P/E :	395 x	263 x	87.7 x	39.5 x		
		-----	-----	-----	-----		
EPS COMPOUND GROWTH RATE							
NA %	NA x	NA %	0.0 %	350 %	122.0 %	200.0 %	

**BASIS OF RECOMMENDATION**

Sells wholesale name brand drugs, medical products, its anti-stick safety syringe, its "Elite" brand and private label medical products and its "Tru-Choice" over-the-counter drugs, which are provided to the company by various suppliers. MHUT's syringe is, so far, the only one to make an approved list generated by the Federal government, a list from which hospitals will be buying their syringes. Competitor company, Med-Design's product is not listed. I believe that explosive sales growth will make earning explode in the coming year.

**POSITIVES**

- \* Company has an OSHA approved safety needle; competitors do not.
- \* MHUT recently hired former top salesmen from Becton Dickinson to market its product. These sales people have an extensive industry contact list.
- \* Sales in recent quarters have gone from \$400 thousand to over \$2.2 million.

**NEGATIVES**

- \* MHUT is a small cap company, and has a much higher inherent risk level.
- \* Competitors may yet get a product approved for the OSHA list by January, crimping MHUT's possible sales.

ANALYST	DATE OF STOCK PRICE	SPX PRICE THAT DATE	DATE OF THIS REPORT
Gary Vassalotti	August 30, 2001	\$ 1049.02	August 30, 2001

FILE: F:\INVEST\FORM.DOC